Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

Hung Ming Wang; Pei Jen Lou; Muh Hwa Yang; Tein Hua Chen; Ming Yu Lien; Jin Ching Lin; Jo Pai Chen; Wei Chen Lu; Hsueh Ju Lu; Tai Lin Huang; Chia Jui Yen; Shang Yin Wu; Hui Ching Wang; Meng Che Hsieh

doi:10.1007/s11523-023-01028-7

Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

Hung Ming Wang
, Pei Jen Lou
, Muh Hwa Yang
, Tein Hua Chen
, Ming Yu Lien
, Jin Ching Lin
, Jo Pai Chen
, Wei Chen Lu
, Hsueh Ju Lu
, Tai Lin Huang
, Chia Jui Yen
, Shang Yin Wu
, Hui Ching Wang
, Meng Che Hsieh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs. Objective: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Patients and Methods: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed. Results: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS. Conclusions: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.

Original language	English
Pages (from-to)	51-58
Number of pages	8
Journal	Targeted Oncology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1007/s11523-023-01028-7
State	Published - Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11523-023-01028-7

Cite this

Wang, H. M., Lou, P. J., Yang, M. H., Chen, T. H., Lien, M. Y., Lin, J. C., Chen, J. P., Lu, W. C., Lu, H. J., Huang, T. L., Yen, C. J., Wu, S. Y., Wang, H. C., & Hsieh, M. C. (2024). Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08). Targeted Oncology, 19(1), 51-58. https://doi.org/10.1007/s11523-023-01028-7

@article{b761aea5f3fc41998b576d71037a05c0,

title = "Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)",

abstract = "Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs. Objective: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Patients and Methods: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed. Results: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS. Conclusions: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.",

author = "Wang, \{Hung Ming\} and Lou, \{Pei Jen\} and Yang, \{Muh Hwa\} and Chen, \{Tein Hua\} and Lien, \{Ming Yu\} and Lin, \{Jin Ching\} and Chen, \{Jo Pai\} and Lu, \{Wei Chen\} and Lu, \{Hsueh Ju\} and Huang, \{Tai Lin\} and Yen, \{Chia Jui\} and Wu, \{Shang Yin\} and Wang, \{Hui Ching\} and Hsieh, \{Meng Che\}",

note = "Publisher Copyright: {\textcopyright} 2024, The Author(s).",

year = "2024",

month = jan,

doi = "10.1007/s11523-023-01028-7",

language = "English",

volume = "19",

pages = "51--58",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Adis",

number = "1",

}

Wang, HM, Lou, PJ, Yang, MH, Chen, TH, Lien, MY, Lin, JC, Chen, JP, Lu, WC, Lu, HJ, Huang, TL, Yen, CJ, Wu, SY, Wang, HC & Hsieh, MC 2024, 'Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)', Targeted Oncology, vol. 19, no. 1, pp. 51-58. https://doi.org/10.1007/s11523-023-01028-7

TY - JOUR

T1 - Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

T2 - A Nationwide Population-Based Study (THNS-2021-08)

AU - Wang, Hung Ming

AU - Lou, Pei Jen

AU - Yang, Muh Hwa

AU - Chen, Tein Hua

AU - Lien, Ming Yu

AU - Lin, Jin Ching

AU - Chen, Jo Pai

AU - Lu, Wei Chen

AU - Lu, Hsueh Ju

AU - Huang, Tai Lin

AU - Yen, Chia Jui

AU - Wu, Shang Yin

AU - Wang, Hui Ching

AU - Hsieh, Meng Che

PY - 2024/1

Y1 - 2024/1

N2 - Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs. Objective: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Patients and Methods: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed. Results: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS. Conclusions: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.

AB - Background: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs. Objective: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Patients and Methods: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed. Results: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS. Conclusions: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.

UR - https://www.scopus.com/pages/publications/85183363244

U2 - 10.1007/s11523-023-01028-7

DO - 10.1007/s11523-023-01028-7

M3 - Article

C2 - 38285067

AN - SCOPUS:85183363244

SN - 1776-2596

VL - 19

SP - 51

EP - 58

JO - Targeted Oncology

JF - Targeted Oncology

IS - 1

ER -

Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this